Processa Pharmaceuticals (OTCMKTS:PCSA) Stock Rating Lowered by ValuEngine

Processa Pharmaceuticals (OTCMKTS:PCSA) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Friday, ValuEngine reports.

Shares of OTCMKTS PCSA traded up $0.50 during midday trading on Friday, hitting $2.50. 200 shares of the stock traded hands, compared to its average volume of 979. The firm has a 50-day moving average of $2.50 and a two-hundred day moving average of $2.47. Processa Pharmaceuticals has a one year low of $1.70 and a one year high of $4.00.

Processa Pharmaceuticals (OTCMKTS:PCSA) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.03) earnings per share for the quarter.

About Processa Pharmaceuticals

Processa Pharmaceuticals, Inc, a pharmaceutical company, engages in the clinical development of drug products for the unmet medical needs. Its lead product candidate is PCS-499, an oral tablet for the treatment of necrobiosis lipoidica and radiation-induced fibrosis in head and neck cancer patients. The company is based in Hanover, Maryland.

See Also: What factors cause inflation to rise?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Processa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Processa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.